Ascensia Diabetes Care Overview
Pro stress-test →Ascensia Diabetes Care was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings, and is a global company entirely dedicated to improving the health and lives of people with diabetes. The company's products are sold in more than 90 countries worldwide and it is home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems.
Strategic Profile
Pro stress-test →Ascensia is the exclusive global distribution partner for Eversense® - the first and only long-term Continuous Glucose Monitoring System. The company combines established diabetes-management technology with expansion into continuous glucose monitoring, positioning itself as a comprehensive diabetes care provider. Ascensia has formed alliances and partnerships with other companies and organizations to advance diabetes care, including partnerships with Medtronic, Voluntis, and Insulet.
Competitive Landscape
Pro stress-test →Ascensia competes in both blood glucose monitoring and continuous glucose monitoring markets against diversified medical device companies including Abbott (FreeStyle Libre), Dexcom (G6/G7), Medtronic (Guardian), and LifeScan (OneTouch). The company's strength lies in its dual-product portfolio (CONTOUR systems for traditional BGM and exclusive Eversense distribution for implantable CGM) and global distribution reach, though it operates at smaller scale than larger multinational competitors.
Industry Context
Ascensia Diabetes Care operates in Blood Glucose Monitoring & Continuous Glucose Monitoring Systems.
Key facts
Founded: 2016 · Headquarters: Basel, Switzerland · Employees: ~1.4K · Revenue: $750M (April 2025)